Increased Circulating Osteopontin Levels Promote Primary Tumour Growth, but Do Not Induce Metastasis in Melanoma

Osteopontin (OPN) is a phosphoprotein with diverse functions in various physiological and pathological processes. OPN expression is increased in multiple cancers, and OPN within tumour tissue has been shown to promote key stages of cancer development. OPN levels are also elevated in the circulation of cancer patients, which in some cases has been correlated with enhanced metastatic propensity and poor prognosis. However, the precise impact of circulating OPN (cOPN) on tumour growth and progression remains insufficiently understood. To examine the role of cOPN, we used a melanoma model, in which we stably increased the levels of cOPN through adeno-associated virus-mediated transduction. We found that increased cOPN promoted the growth of primary tumours, but did not significantly alter the spontaneous metastasis of melanoma cells to the lymph nodes or lungs, despite an increase in the expression of multiple factors linked to tumour progression. To assess whether cOPN has a role at later stages of metastasis formation, we employed an experimental metastasis model, but again could not detect any increase in pulmonary metastasis in animals with elevated levels of cOPN. These results demonstrate that increased levels of OPN in the circulation play distinct roles during different stages of melanoma progression.

[1]  W. Jiang,et al.  Osteopontin and Cancer: Insights into Its Role in Drug Resistance , 2023, Biomedicines.

[2]  M. Shinohara,et al.  Osteopontin (OPN)/SPP1: From its biochemistry to biological functions in the innate immune system and the central nervous system (CNS). , 2022, International immunology.

[3]  S. Liebner,et al.  Anti-osteopontin therapy leads to improved edema and infarct size in a murine model of ischemic stroke , 2022, Scientific Reports.

[4]  Y. Kariya,et al.  Osteopontin in Cancer: Mechanisms and Therapeutic Targets , 2022, International Journal of Translational Medicine.

[5]  Xiaoxiong Jia,et al.  Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood–brain barrier in acute ischemic stroke , 2022, Acta Neuropathologica.

[6]  Yaohong Wu,et al.  Osteopontin in autoimmune disorders: current knowledge and future perspective , 2022, Inflammopharmacology.

[7]  S. Dietmann,et al.  Identification of kidney injury released circulating osteopontin as causal agent of respiratory failure , 2022, Science advances.

[8]  W. Tong,et al.  Macrophages in epididymal adipose tissue secrete osteopontin to regulate bone homeostasis , 2022, Nature communications.

[9]  G. Cappellano,et al.  High levels of circulating osteopontin in inflammatory lung disease regardless of SARS‐CoV‐2 infection , 2021, EMBO molecular medicine.

[10]  M. Rothley,et al.  Quantitative Detection of Disseminated Melanoma Cells by Trp-1 Transcript Analysis Reveals Stochastic Distribution of Pulmonary Metastases , 2021, Journal of clinical medicine.

[11]  J. Utikal,et al.  IER2-induced senescence drives melanoma invasion through osteopontin , 2021, Oncogene.

[12]  G. Long,et al.  Immune checkpoint inhibitors in melanoma , 2021, The Lancet.

[13]  Yukio Fujiwara,et al.  Soluble Factors Involved in Cancer Cell–Macrophage Interaction Promote Breast Cancer Growth , 2021, AntiCancer Research.

[14]  A. Mirzaei,et al.  Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors , 2021, Journal of bone oncology.

[15]  Changzheng Huang,et al.  The role of osteopontin in the development and metastasis of melanoma , 2021, Melanoma research.

[16]  Dafeng Yang,et al.  Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression , 2021, Cancers.

[17]  Kebin Liu,et al.  Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation , 2020, Cancers.

[18]  G. Cappellano,et al.  Osteopontin binds ICOSL promoting tumor metastasis , 2020, Communications biology.

[19]  Juan Su,et al.  BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway , 2020, Theranostics.

[20]  Deepali V. Sawant,et al.  Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer , 2020, Cell.

[21]  Chaowei Wang,et al.  Osteopontin in Bone Metabolism and Bone Diseases , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[22]  R. Matusik,et al.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia , 2019, bioRxiv.

[23]  Jun Li,et al.  Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. , 2019, Cancer cell.

[24]  Z. Lok,et al.  Osteopontin in Vascular Disease: Friend or Foe? , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[25]  G. Gao,et al.  Adeno-associated virus vector as a platform for gene therapy delivery , 2019, Nature Reviews Drug Discovery.

[26]  K. Ozato,et al.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion , 2018, The Journal of clinical investigation.

[27]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[28]  M. Gezmen-Karadag,et al.  The multiple functions and mechanisms of osteopontin. , 2018, Clinical biochemistry.

[29]  Hailin Zhao,et al.  The role of osteopontin in the progression of solid organ tumour , 2018, Cell Death & Disease.

[30]  M. Perelman,et al.  Metastatic cardiac tumors: from clinical presentation through diagnosis to treatment , 2018, BMC Cancer.

[31]  W. Syn,et al.  Osteopontin splice variants and polymorphisms in cancer progression and prognosis. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[32]  A. Chiocchetti,et al.  Osteopontin at the Crossroads of Inflammation and Tumor Progression , 2017, Mediators of inflammation.

[33]  W. Jiang,et al.  Human osteopontin: Potential clinical applications in cancer (Review) , 2017, International journal of molecular medicine.

[34]  I. Giopanou,et al.  Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis , 2017, Oncoimmunology.

[35]  R. Chen,et al.  Osteopontin facilitates tumor metastasis by regulating epithelial–mesenchymal plasticity , 2016, Cell Death and Disease.

[36]  M. Colombo,et al.  Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers , 2015, Oncotarget.

[37]  R. Ádány,et al.  The role of osteopontin expression in melanoma progression , 2015, Tumor Biology.

[38]  S. Aamdal,et al.  Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial , 2015, Cancer Immunology, Immunotherapy.

[39]  T. Geiger,et al.  Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. , 2015, Cancer research.

[40]  T. Padera,et al.  The lymph node microenvironment and its role in the progression of metastatic cancer. , 2015, Seminars in cell & developmental biology.

[41]  Yeonseok Chung,et al.  Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. , 2014, Cancer research.

[42]  Xiao-Fei Liu,et al.  Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[43]  D. Bruemmer,et al.  Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes , 2014, Molecular metabolism.

[44]  G. Kundu,et al.  Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin , 2014, Oncogene.

[45]  D. Bishop,et al.  Plasma osteopontin concentrations in patients with cutaneous melanoma , 2013, Oncology reports.

[46]  Dhiraj Kumar,et al.  Functional Characterization of Stromal Osteopontin in Melanoma Progression and Metastasis , 2013, PloS one.

[47]  C. Berking,et al.  Osteopontin expression in plasma of melanoma patients and in melanocytic tumours , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[48]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[49]  E. Kraynov,et al.  Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer , 2012, Journal of experimental & clinical cancer research : CR.

[50]  K. Alitalo,et al.  Induced Pluripotent Stem Cell Clones Reprogrammed via Recombinant Adeno-Associated Virus-Mediated Transduction Contain Integrated Vector Sequences , 2012, Journal of Virology.

[51]  Guoxin Zhang,et al.  Osteopontin Enhances the Expression and Activity of MMP-2 via the SDF-1/CXCR4 Axis in Hepatocellular Carcinoma Cell Lines , 2011, PloS one.

[52]  E. Kizana,et al.  SUMO1-dependent modulation of SERCA2a in heart failure , 2011, Nature.

[53]  A. Chambers,et al.  Pre- and post-translational regulation of osteopontin in cancer , 2011, Journal of Cell Communication and Signaling.

[54]  M. Shinohara,et al.  Intracellular osteopontin (iOPN) and immunity , 2011, Immunologic research.

[55]  C. Comi,et al.  The role of osteopontin in neurodegenerative diseases. , 2011, Journal of Alzheimer's disease : JAD.

[56]  Harish Srinivasan,et al.  Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[57]  E. Elias,et al.  Cytokines and Growth Factors Expressed by Human Cutaneous Melanoma , 2010, Cancers.

[58]  Hao Wang,et al.  A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo , 2010, Cancer Immunology, Immunotherapy.

[59]  Jingwu Z. Zhang,et al.  Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[60]  S. Stewart,et al.  Senescent stromal-derived osteopontin promotes preneoplastic cell growth. , 2009, Cancer research.

[61]  C. Betsholtz,et al.  Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. , 2009, Cancer research.

[62]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[63]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  M. Shinohara,et al.  Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells , 2008, Proceedings of the National Academy of Sciences.

[65]  M. Nosrati,et al.  Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.

[66]  E. Ukkonen,et al.  Systematic search for the best gene expression markers for melanoma micrometastasis detection , 2007, The Journal of pathology.

[67]  M. Noda,et al.  Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration , 2007, Journal of cellular biochemistry.

[68]  Gregory E. J. Harding,et al.  Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. , 2007, American journal of physiology. Cell physiology.

[69]  M. Kaplan,et al.  Plasma osteopontin is an independent prognostic marker for head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  M. Ringnér,et al.  Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. , 2006, Carcinogenesis.

[71]  Q. Ye,et al.  The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma , 2006, Journal of Cancer Research and Clinical Oncology.

[72]  V. Bramwell,et al.  Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[73]  D. Denhardt Osteopontin expression correlates with melanoma invasion. , 2005, The Journal of investigative dermatology.

[74]  Quynh-Thu Le,et al.  Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  H. Cantor,et al.  Phosphorylation‐dependent interaction of osteopontin with its receptors regulates macrophage migration and activation , 2002, Journal of leukocyte biology.

[76]  M. Noda,et al.  Osteopontin Deficiency Reduces Experimental Tumor Cell Metastasis to Bone and Soft Tissues , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[77]  J. Sleeman,et al.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. , 1999, Cancer research.

[78]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  M. Glimcher,et al.  Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.

[80]  M C Farach-Carson,et al.  Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. , 1993, The Journal of biological chemistry.

[81]  R. Hynes,et al.  Transformed mammalian cells secrete specific proteins and phosphoproteins , 1979, Cell.